These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 19671856

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL.
    Cancer Res; 2005 Mar 01; 65(5):1710-8. PubMed ID: 15753366
    [Abstract] [Full Text] [Related]

  • 5. Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors.
    Toma CD, Svoboda M, Arrich F, Ekmekcioglu C, Assadian O, Thalhammer T.
    J Pineal Res; 2007 Sep 01; 43(2):206-13. PubMed ID: 17645699
    [Abstract] [Full Text] [Related]

  • 6. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.
    Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, Binazzi R, Piccari GG, Ramazzotti G, Gaboardi GC, Cocco L, Vitale M.
    Int J Oncol; 2006 Jan 01; 28(1):127-33. PubMed ID: 16327988
    [Abstract] [Full Text] [Related]

  • 7. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
    Sandra F, Hendarmin L, Nakamura S.
    Oral Oncol; 2006 Apr 01; 42(4):415-20. PubMed ID: 16413220
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T.
    Cancer; 2004 Oct 15; 101(8):1794-802. PubMed ID: 15386310
    [Abstract] [Full Text] [Related]

  • 10. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.
    Mori K, Berreur M, Blanchard F, Chevalier C, Guisle-Marsollier I, Masson M, Rédini F, Heymann D.
    Oncol Rep; 2007 Dec 15; 18(6):1365-71. PubMed ID: 17982618
    [Abstract] [Full Text] [Related]

  • 11. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
    Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC.
    J Cell Biochem; 2009 Sep 01; 108(1):106-16. PubMed ID: 19544400
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.
    Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V, Blanchard F, Gouin F, Pitard B, Heymann D, Redini F.
    Cancer Res; 2007 Aug 01; 67(15):7308-18. PubMed ID: 17671200
    [Abstract] [Full Text] [Related]

  • 13. 2-methoxyestradiol-mediated anti-tumor effect increases osteoprotegerin expression in osteosarcoma cells.
    Benedikt MB, Mahlum EW, Shogren KL, Subramaniam M, Spelsberg TC, Yaszemski MJ, Maran A.
    J Cell Biochem; 2010 Apr 01; 109(5):950-6. PubMed ID: 20082321
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
    Nadiminty N, Lou W, Lee SO, Mehraein-Ghomi F, Kirk JS, Conroy JM, Zhang H, Gao AC.
    Clin Cancer Res; 2006 Mar 01; 12(5):1420-30. PubMed ID: 16533764
    [Abstract] [Full Text] [Related]

  • 15. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
    Sun J, Fu ZM, Fang CQ, Li JH.
    Chin Med J (Engl); 2007 Mar 05; 120(5):400-4. PubMed ID: 17376311
    [Abstract] [Full Text] [Related]

  • 16. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis.
    Harada M, Osuga Y, Hirata T, Hirota Y, Koga K, Yoshino O, Morimoto C, Fujiwara T, Momoeda M, Yano T, Tsutsumi O, Taketani Y.
    Hum Reprod; 2004 Oct 05; 19(10):2188-91. PubMed ID: 15242994
    [Abstract] [Full Text] [Related]

  • 17. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
    Chamoux E, Houde N, L'Eriger K, Roux S.
    J Cell Physiol; 2008 Aug 05; 216(2):536-42. PubMed ID: 18338379
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
    Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F.
    Clin Cancer Res; 2010 Apr 15; 16(8):2363-74. PubMed ID: 20371692
    [Abstract] [Full Text] [Related]

  • 19. Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease.
    Reenaers C, Franchimont N, Oury C, Belaiche J, Malaise M, Bours V, Theatre E, Delvenne P, Louis E.
    Scand J Gastroenterol; 2008 Apr 15; 43(11):1334-45. PubMed ID: 18942021
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.
    Goda AE, Yoshida T, Horinaka M, Yasuda T, Shiraishi T, Wakada M, Sakai T.
    Oncogene; 2008 May 29; 27(24):3435-45. PubMed ID: 18193086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.